Underwater endoscopic mucosal resection for neoplasms in the pyloric ring of the stomach: Four case reports

BACKGROUND Tumors located in the pylorus are technically more complex to resect by endoscopic resection,as the anatomical characteristics of this region can affect the adequate assessment of margins and performance of the procedure.We reported the results of underwater endoscopic mucosal resection(UEMR)of benign mucosal neoplasms located in the pyloric ring.CASE SUMMARY This case series describes 4 patients with 4 mucosal neoplasms located in the pyloric ring.The diameter of each neoplasm was less than 15 mm.We performed UEMR for the lesions.Water immersion enabled slight floating of the lesions,resulting in easy identification.We achieved en bloc resection with a snare and electrosurgical unit.All procedure were performed within 3 min without adverse events.Pathologic examination showed low-grade dysplasia with clear resection margins in one case and hyperplastic polyps in three cases.CONCLUSION UEMR can be an effective and safe treatment method for neoplasms in the gastric pyloric ring.

Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice

Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: Human stom- ach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results: After therapy, the body mass of rhGH groups was significantly increased compared with control group (P<0.05), the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group (P<0.05), but it was no significant difference between rhGH/5-FU groups and control group (P>0.05). The average tumor mass and volume of rhGH groups were not significantly increased compared with control group (P>0.05), but they were significantly reduced in 5-FU group and rhGH/5-FU groups (P<0.05). They were no significant difference between rhGH/5- FU groups and 5-FU group (P>0.05). After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index (PI) were not significantly changed in rhGH groups compared with control group (P>0.05), and the same with rhGH/5-FU groups compared with 5-FU group (P>0.05). The difference caused by dose of rhGH was not significant. Conclusion: rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics.

Gastric leiomyoma presenting as an endophytic growth of cardia of the stomach: A case report

Gastric leiomyomas are rare submucosal neoplasms arising from smooth muscle cells.It accounts for approximately 2.5%of all gastric tumours,is slow growing and rarely causes symptoms such as upper abdominal discomfort and dyspepsia.1 On imaging,they appear similar to gastrointestinal stromal tumours(GISTs)and can be intraluminal or extraluminal.Diagnosis is mostly confirmed by histopathological examination of the tumour.Surgical resection of the tumour is the main treatment option.Here,we present a case of laparoscopic resection of an endophytic gastric tumour that turned out to be a leiomyoma.

Metastatic stomach lymphoepithelioma-like carcinoma and immune checkpoint inhibitor therapy:A case report

BACKGROUND Pulmonary lymphoepithelioma-like carcinoma(PLELC)is a rare type of nonsmall-cell lung cancer.Stomach lymphoepithelioma-like carcinoma(LELC)metastasis secondary to PLELC has not been reported recently.CASE SUMMARY A 64-year-old female was admitted to our hospital for a regular gastroscopy examination with a 6-year history of surgical resection for left PLELC.Positron emission tomography/computed tomography suggested high accumulation of 18F-fludeoxyglucose in the gastric cardia region.Upper gastrointestinal endoscopy confirmed a large mass at the stomach fundus.Immunohistochemistry(IHC)of the biopsy suggested metastatic stomach LELC.Proximal gastrectomy showed that this 6.5 cm×5.0 cm mass was located in the stomach fundus near the cardia.Histopathological examination showed a poorly differentiated carcinoma with prominent lymphoplasmacytic infiltration.IHC demonstrated that the tumor was positive for CK(AE1/AE3),p63,p40,p53,Ki-67(70%),and EGFR(3+)and negative for CK7,CK20,Her2,and CD10.In situ hybridization analysis showed positive staining Epstein-Barr virus-encoded RNA.Tumor programmed cell death ligand 1(PD-L1)expression score was 98%,and the combined positive score was 100,with no evidence of microsatellite instability.Thus,the patient was unequivocally diagnosed with metastatic stomach LELC secondary to pulmonary LELC.After discharge,this patient underwent PD-1 inhibitor treatment(toripalimab,240 mg)every 3 wk for ten cycles,and she has had no tumor recurrence.CONCLUSION For gastric LELC metastasis,PD-1 inhibitor therapy could become a new therapeutic approach,though there is still no evidence from large data sets to support this.

Analysis of Humanistic Nursing Care in Regulating the Emotion, Satisfaction, and Sleep Quality of Inpatients with Hematologic Neoplasms

Objective:To explore the clinical application value of humanistic nursing care in the treatment of hematologic neoplasm inpatients.Methods:Fifty-two patients with hematologic neoplasms admitted to a hospital from May 2019 to February 2022 were selected as the research subjects.According to a random number table,they were divided into two groups:the control group(n=25,routine clinical nursing)and the observation group(n=27,humanistic nursing care).The negative emotion score,nursing satisfaction,and sleep quality were compared between the two groups under different nursing modes.Results:The SAS and SDS scores before and after nursing were compared between the two groups.There was no significant difference between the two groups before nursing(p>0.05).However,the SDS and SAS scores in the two groups after nursing were lower than those before nursing,in which the observation group was slightly lower than the control group,and the difference was statistically significant(p<0.001).In terms of nursing satisfaction,it was as high as 96.29%in the observation group,whereas in the control group,the satisfaction rate was only 72.00%;the PSQI scores were compared between the two groups before and after nursing,and there was no significant difference between the two groups before nursing(p>0.05).However,the PSQI scores and total score of the observation group after nursing were lower than those of the control group(p<0.001).Conclusion:In the clinical treatment of patients with hematologic neoplasms,the implementation of humanistic nursing care can significantly improve patients’anxiety,depression,other negative emotions,sleep quality,and nursing satisfaction,all of which have significance in promoting the prognosis of patients and improving their quality of life.

Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies:Insights from a Chinese single-center experience(1997-2021)

Background:Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors,including immune system compromise and chemotherapy-related effects.However,the incidence and associated risk factors in older patients remain poorly understood.This study aimed to assess the incidence,identify risk factors,and evaluate their impact on survival outcomes among older patients with hematological malignancies.Methods:This retrospective single-center study analyzed data from 163 patients,focusing on the occurrence of second primary neoplasms.Cumulative incidence rates were calculated,and risk factor analysis was conducted using a competing risk model.Results:Among 124 eligible patients with a total follow-up duration of 572.57 person-years,the incidence rate of second primary neoplasms was 15.72/1000 person-years.The standardized incidence ratio(SIR)was 0.81(95%confidence interval[CI][0.39–1.48],P=0.518).History of radiotherapy emerged as a significant risk factor(subdistribution hazard ratio[SHR]=21.61[2.81–166.14],P=0.003),whereas regular natural killer(NK)cell infusion was associated with reduced risk(SHR=3.25 e8[9.81 e9–1.08 e7],P<0.001).Conclusions:These findings underscore the importance of informing older patients with hematological malignancies about the long-term risks of second primary neoplasms.Healthcare providers should carefully weigh risk factors when formulating treatment strategies.The results are valuable for investigating the fundamental principles underlying the occurrence and progression of second primary neoplasms.

Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era

Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy.

Proton pump inhibitors and stomach neoplasm

This study aimed to explore the relationship between proton pump inhibitors(PPIs)and gastric tumors and determine the reasons behind these connections.We reviewed studies on PPIs and stomach tumors.We explored the relationship between PPIs and different types of gastric neoplasms according to the classification of gastric neoplasms.Long-term use of PPIs is associated with stomach infection,high gastrin levels,and rebound acid hypersecretion,which are directly or indirectly related to the development of gastric neoplasms.PPIs can increase the risk of gastric fundal polyps.Further evidence is needed to prove that it can increase the risk of gastric cancer.

Extraskeletal Ewing sarcoma of the stomach:A rare case report

BACKGROUND Extraskeletal Ewing sarcoma(EES)is a rare and highly malignant small round cell tumor associated with a poor clinical outcome.Ewing sarcoma(ES)involving the stomach is an uncommon presentation and can be easily confused with other small round cell tumors.We herein present a rare case of ES involving the gastric area.CASE SUMMARY We report a case of gastric ES in a 19-year-old female patient who initially presented with a complaint of a tender epigastric mass for 5 d.Contrast-enhanced abdominal computed tomography revealed a soft-tissue-density mass with a diameter of 8.5 cm between the liver and stomach;the mass was connected to the gastric antrum.Then,the mass was surgically excised completely.Upon histopathological,immunophenotype and molecular analysis,the mass was identified to be a primary gastric ES.CONCLUSION EES is an aggressive tumor with poor prognosis.Therefore,early diagnosis and timely intervention are essential for a good prognosis.It is imperative for us to raise awareness about this rare tumor.Surgical resection is still the best treatment option.

血液肿瘤患儿合并脓毒血症的病原学特点及临床特征

目的 探讨血液肿瘤患儿血流感染的病原菌特点,为临床合理使用抗感染药物提供依据。方法 回顾分析2021年1月至2021年12月在苏州大学附属儿童医院住院的血液肿瘤患儿,出院诊断脓毒血症/脓毒性休克的连续病例,收集抗生素使用前送检双侧血培养患儿的临床及病原学结果及药敏数据。结果 共963例血液肿瘤患儿合并脓毒血症,血培养阳性患儿共141例,共获得病原菌株156株,送检阳性率为14.64%。本组患儿中位年龄82(31.5,131)月龄,男女比2.05∶1,血培养阳性的病原菌中革兰阴性菌占43.59%,前3位分别是铜绿假单胞菌、肺炎克雷伯杆菌、大肠埃希菌,其中哌拉西林他唑巴坦、头孢吡肟、丁胺卡那霉素敏感率均大于85%;亚胺培南对铜绿假单胞菌敏感率为50%,美罗培南对铜绿假单胞菌56.25%,亚胺培南、美罗培南对大肠埃希菌和肺炎克雷伯杆菌总体敏感率93%;其中产ESBL肺炎克雷伯杆菌5株,大肠埃希菌3株。革兰阳性菌占55.77%,前3位分别是表皮葡萄球菌、人葡萄球菌、缓症链球菌,利奈唑胺、万古霉素敏感率均为100%;真菌占0.64%。141例血培养阳性患儿中共109例存在粒细胞缺乏,76例脓毒症患儿发生于化疗后骨髓抑制期,42例发生于移植后获得性免疫缺陷,23例发生于骨髓恢复期;发生脓毒症休克共24例,占比17.02%;死亡15例,占10.64%。结论 恶性血液肿瘤患儿脓毒血症常见于学龄期儿童,男童多于女童,绝大多数发生于粒细胞缺乏期;其病原体分布,根据血培养的病原学结果,以革兰阳性菌为主;但引起脓毒血症患儿死亡的病原体中,革兰阴性菌占了绝大多数。革兰阳性菌对万古霉素、利奈唑胺保持很高的敏感率,革兰阴性菌则对哌拉西林他唑巴坦、头孢吡肟、丁胺卡那霉素较高的敏感率。

胃肝样腺癌的CT特征

目的分析胃肝样腺癌的临床和CT特征,提高对本病的认识。资料与方法回顾性分析2012年9月—2023年4月苏州大学附属第一医院经病理证实的38例胃肝样腺癌患者的临床病理资料、实验室检查、CT资料,分析病灶大小、形态、密度、边界、强化方式、转移及侵犯等情况,总结其临床及CT特征。结果38例患者中,血清甲胎蛋白水平升高24例,免疫组化甲胎蛋白表达阳性32例。CT表现为胃壁增厚,门静脉期病变最大截面长径2.38~11.95cm,中位数为5.200(3.365,7.215)cm,23例伴溃疡,20例内见坏死,25例周围侵犯,14例出现肝脏转移,5例出现门静脉系统癌栓。结论胃肝样腺癌为罕见肿瘤,血清甲胎蛋白常增高,CT增强检查肿瘤常较大,可见坏死,渐进性或持续强化,易发生转移、侵犯门静脉,认识这些特征有助于提高诊断水平。

PLR、NLR、CRP联合评估进展期胃癌腹膜腔转移的价值研究

目的探讨血小板计数/淋巴细胞计数(platelet count/lymphocyte count,PLR)、中性粒细胞计数/淋巴细胞计数(neutrophil count/lymphocyte count,NLR)、C反应蛋白(C-reactive protein,CRP)评估进展期胃癌腹膜腔转移的价值。方法回顾性选取江苏省徐州市肿瘤医院进展期胃癌患者124例,根据是出现腹膜腔转移分为腹腔转移组36例、非腹腔转移组88例。比较2组临床资料、病理学参数及CRP、PLR、NLR,Logistic分析进展期胃癌腹膜腔转移影响因素,构建Logistic回归模型,受试者工作特征(receiver operating characteristics,ROC)曲线评估其对腹膜腔转移的预测价值。结果腹腔转移组肿瘤直径大于非腹腔转移组,浸润深度、TNM分期及PLR、NLR、CRP水平高于腹腔转移组,组织学分化程度低于非腹腔转移组(P<0.05);排除PLR、NLR和CRP之外的混杂因素肿瘤大小、浸润深度、TNM分期和组织学分化,建立Logistic模型,对其行多因素分析,显示PLR、NLR和CRP是进展期胃癌腹膜腔转移的危险因素(P<0.05);构建风险预测模型:logit(p)=PLR×1.416+NLR×1.149+CRP×1.088;模型预测价值:ROC分析,logit(p)>0.5时,AUC值为0.755,χ^(2)为10.212,诊断敏感度为80.95%,特异度为61.64%。结论进展期胃癌腹膜腔转移与PLR、NLR、CRP水平及相关临床特征相关,根据PLR、NLR、CRP和相关临床因素构建的预测模型对其具有较高预测价值,可为临床决策提供依据。

661例胃癌患者临床病理特征分析

目的探讨新乡医学院第一附属医院收治的胃癌的临床病理特征。方法回顾性分析2019年5月至2023年4月该院收治的661例连续胃癌手术病例临床病理资料。统计分析年龄、性别、癌肿部位、pT分期、淋巴结转移及脉管癌栓、神经侵犯情况。结果661例胃癌病例中男性499例,女性162例。661例胃癌患者年龄多处于46岁~75岁之间,56岁~70岁为发病高峰,平均年龄为(63.03±9.07)岁,其中男性平均年龄为(63.23±8.95)岁,女性平均年龄为(62.42±9.44)岁。不同性别组年龄相比差异无统计学意义(P>0.05)。癌肿部位以食管胃结合部腺癌为主(72.61%),不同性别组胃癌癌肿分布部位差异无统计学意义(P>0.05)。组织学类型以腺癌为主(98.18%);分化程度以低-中分化胃癌为主(88.65%)。胃癌T分期pT3组和pT4a组分别占39.49%和31.47%,随着pT分期的升高,淋巴结转移、神经侵犯、脉管癌栓阳性率逐渐增高,其中,pT3组与pT2组相比,淋巴结转移、神经侵犯、脉管癌栓阳性率差异均有统计学意义(P<0.05)。胃癌癌肿部位不同,淋巴结转移、神经侵犯、脉管癌栓阳性率无显著差别(P>0.05)。结论该院收治的胃癌的临床病理特征如下:多见于中老年男性;以食管胃结合部腺癌为主;分化程度以低-中分化腺癌为主,且与胃癌的原发部位无关;T分期多为T3和T4a期;淋巴结转移、神经侵犯、脉管癌栓的发生与T分期呈正相关,但不同部位胃癌的淋巴结转移、神经侵犯和脉管癌栓发生无明显差异。

基于倾向性评分匹配的T_(4a)期胃癌腔镜辅助与开腹手术近期疗效的对比分析

目的:探讨T_(4a)期胃癌行腹腔镜辅助D2根治术的近期疗效。方法:采用倾向性评分匹配,分析2014年1月至2020年12月为T_(4a)期胃腺癌患者行D2淋巴结清扫的临床资料。将患者分为开腹组(n=362)与腹腔镜组(n=134),通过倾向性评分匹配对数据进行1∶1匹配,匹配容差设为0.03。最终获得两组病例各134例。比较两组手术情况、术后并发症、术后炎性指标变化及2年总生存率。结果:倾向性匹配后,两组基线资料具有可比性(P>0.05)。两组术后首次进食时间、住院时间、并发症情况差异均无统计学意义(P>0.05);腹腔镜组与开腹组手术时间[240(203.75,256.25)min vs.140(120,190)min,P<0.05]、术中出血量[200(100,300)mL vs.200(200,300)mL,P<0.05]、淋巴结清扫数量[20.5(17,27.25)vs.16(10,23),P<0.05]、切口长度[5(5,6)cm vs.12(10,15)cm,P<0.05]、术后排气时间[4(3,6)d vs.5(3,6)d,P<0.05]、术后下床活动时间[2(2,3)d vs.3(2,3)d,P<0.05]差异均有统计学意义。两组术前中性粒细胞-淋巴细胞比值、血小板-淋巴细胞比值、淋巴细胞-单核细胞比值差异无统计学意义(P>0.05),术后血小板-淋巴细胞比值差异无统计学意义,腹腔镜组中性粒细胞-淋巴细胞比值低于开腹组,淋巴细胞-单核细胞比值高于开腹组,差异有统计学意义。开腹组与腹腔镜组术后2年总生存率为53.3%与48.3%,差异无统计学意义(P=0.211)。结论:对于T_(4a)期胃癌,腹腔镜手术后并发症发生率、2年生存率与开腹手术相当,但腹腔镜手术具有创伤小、美观、术后康复快的优势。

1例初始表现为急性弥散性血管内凝血的胃低分化腺癌伴多发转移:^(18)F-FDG PET/CT显像所见

患者女,20岁,无明显诱因阵发性下腹部疼痛伴牙龈出血、皮肤散在瘀斑及肛门坠胀感9天;既往体健。查体:贫血貌,全身皮肤散在片状瘀斑,四肢皮肤干燥;腹部柔软,无压痛及反跳痛。实验室检查:红细胞2.49×10^(12)/L,血小板36×10^(9)/L,血红蛋白70 g/L,血浆鱼精蛋白副凝固实验(+),D-二聚体>20 mg/L,纤维蛋白原降解产物>150.00 mg/L,糖类抗原12573.40 U/ml。

临床资料联合CT影像组学特征评估胃癌程序性死亡配体1状态

目的观察临床资料联合CT影像组学特征评估胃癌程序性死亡配体1(PD-L1)状态的价值。方法回顾性按7∶3比例将277例胃癌患者随机分为训练集(n=195)与验证集(n=82):训练集含PD-L1阳性亚组88例、阴性亚组107例,验证集各含37及45例。比较不同集别亚组间临床及常规CT特征,分析胃癌PD-L1状态的独立影响因素,基于CT筛选影像组学特征,建立临床模型、影像组学模型及临床-影像组学联合模型,观察各模型评估胃癌PD-L1状态的效能。结果训练集亚组间Borrmann分型、cN分期、cM分期、临床分期、肿瘤最大径及厚径差异均有统计学意义(P均<0.05);Borrmann分型、临床分期及肿瘤厚径均为PD-L1阳性的独立影响因素(P均<0.05)。临床模型、影像组学模型及临床-影像组学联合模型评估训练集胃癌PD-L1状态的曲线下面积(AUC)分别为0.748、0.832及0.841,在验证集分别为0.657、0.801及0.789;临床模型的AUC均低于其他模型(P均<0.05)。结论临床资料联合CT影像组学特征有助于评估胃癌PD-L1状态。

晚期胃癌患者预立医疗照护计划准备度现状及影响因素分析

目的调查晚期胃癌患者预立医疗照护计划准备度现状并分析影响因素。方法选取2023年3月-6月我院收治的晚期胃癌患者209例为研究对象,采用一般资料调查表、预立医疗照护计划准备度量表进行调查。结果晚期胃癌患者预立医疗照护计划准备度总分为(66.22±8.02)分,处于中等偏上水平;多元线性回归分析结果显示,年龄、病程、ECOG评分、文化程度是晚期胃癌患者预立医疗照护计划准备度的独立影响因素(P<0.05)。结论晚期胃癌患者预立医疗照护计划准备度处于中等偏上水平,医护人员应提高患者对ACP重要性的认识,同时关注年龄大、病程短、文化程度低、ECOG评分高的患者,促进预立医疗照护计划的普及应用。

血清miR-345、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性分析

【目的】探讨血清微小RNA-345(miR-345)、miR-138及miR-22与晚期胃癌患者化疗敏感性的相关性。【方法】100例均接受同一化疗方案治疗的晚期胃癌患者,依据疗效分为有效组(n=69)及无效组(n=31),比较两组临床病理特征及血清相关指标,绘制受试者工作特征(ROC)曲线分析血清miR-345、miR-138及miR-22预测晚期胃癌化疗效果的价值,采用多因素Logistic回归分析影响患者化疗效果的因素。【结果】Ⅲ期患者的血清miR-345相对表达量低于Ⅳ期患者,miR-138及miR-22相对表达量高于Ⅳ期患者(P<0.05);有效组miR-345低于无效组,miR-138、miR-22高于无效组(P<0.05)。经ROC曲线分析证实,血清miR-345、miR-138及miR-22能用于预测晚期胃癌的化疗效果,其敏感度与特异性分别为0.855、0.935、0.971、0.839和0.884、0.903(均P<0.05)。多因素Logistic回归分析显示,病理分期为Ⅳ期、miR-345≥14.5、miR-138≤2及miR-22≤3.12为晚期胃癌患者化疗效果不佳的危险因素(P<0.05)。【结论】血清miR-345≥14.5、miR-138≤2、miR-22≤3.12均为导致化疗效果不佳的危险因素,其可作为评估患者化疗效果的生物学标志物。

吲哚菁绿标记近红外荧光腹腔镜胃癌根治术的应用研究

目的:探讨吲哚菁绿(ICG)在腹腔镜胃癌根治术中淋巴结定位及清扫的应用价值。方法:回顾分析2018年1月至2019年5月接受腹腔镜胃癌D2根治术的73例胃癌患者的临床资料。其中35例术前经ICG标记后行腹腔镜手术(ICG组),38例行常规腹腔镜胃癌根治术(对照组)。对比分析两组淋巴结清扫总数、手术时间、出血量、术后并发症及住院时间。结果:两组均顺利完成腹腔镜胃癌根治术。ICG组与对照组手术时间[(195.31±35.12)min vs.(201.48±36.57)min,P>0.05]、术中出血量[(90.58±18.27)mL vs.(92.44±20.25)mL,P>0.05]、术后排气时间[(3.25±1.35)d vs.(3.17±1.65)d,P>0.05]、术后住院时间[(12.55±3.25)d vs.(13.50±3.65)d,P>0.05]差异均无统计学意义。两组淋巴结清扫数量差异有统计学意义[(47.71±16.43)枚vs.(30.22±11.67)枚,P<0.05]。术后平均随访(27±13)个月,其中2例吻合口复发,予以手术切除,无死亡病例。结论:ICG成像技术方便、安全、有效,可确保淋巴结清扫的安全性、有效性,避免淋巴结残留。

ADCY7、GPR86、GRIN2D、RGS4对胃癌前病变进展的预测价值

背景:目前临床上尚无有效预测胃癌前病变进展或筛查早期胃癌的生物学标志物。目的:研究腺苷酸环化酶7(ADCY7)、G蛋白偶联受体GPR86、N⁃甲基⁃D⁃天冬氨酸离子能谷氨酸受体2D(GRIN2D)、G蛋白信号调节因子4(RGS4)在不同胃黏膜病变中的表达及其对胃癌前病变进展的预测价值。方法:应用免疫组化法、real-time PCR和蛋白质印迹法检测ADCY7、GPR86、GRIN2D、RGS4在Correa级联各阶段(包括慢性非萎缩性胃炎、慢性萎缩性胃炎、低级别和高级别上皮内瘤变、黏膜层和黏膜下层早期胃癌)以及胃癌与相应癌旁组织间的表达差异。结果:ADCY7、GPR86、GRIN2D、RGS4在胃炎、上皮内瘤变、早期胃癌中的表达呈递增趋势,除GRIN2D在上皮内瘤变与早期胃癌中的表达无明显差异外,两两比较差异均有统计学意义(P均<0.001)。GPR86、GRIN2D mRNA和蛋白在胃癌组织中的表达显著高于癌旁>5 cm组织(P均<0.05);RGS4蛋白在胃癌组织中的表达高于癌旁>5 cm组织,其mRNA表达趋势则相反(P均<0.05);ADCY7仅蛋白表达在胃癌与癌旁>5 cm组织间差异显著(P<0.05)。结论:ADCY7、GPR86、GRIN2D、RGS4在Correa级联各阶段以及胃癌与相应癌旁组织间的表达变化提示其参与了胃癌前病变的发生、发展,可能具有预测胃癌前病变进展的价值。